Arnold C Hanish sold $17 of DCOY
director at Salarius Pharmaceuticals, Inc.. 27 shares at an average of $0.64, traded Dec 30, 2025, filed Jan 2, 2026.
Score components
- +15RoleDirector
- 0Trade size$17 at market
- 0Share of holdings soldSold 0.5% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +18.3%, 3m -25.9%, 6m -6.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001615219-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 30, 2025 | SOpen-market sale Common Stockindirect: By Arnold C. Hanish Trust | -15 | $0.64 | $10 | 5,000 | Jan 2, 2026 |
| Dec 30, 2025 | SOpen-market sale Common Stock | -12 | $0.64 | $8 | 0 | Jan 2, 2026 |
Related signals
Other insiders at Salarius Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Salarius Pharmaceuticals, Inc. | Arnold C Hanish director | $3,741 5,000 shares | first purchase | |
| 40Moderate | Salarius Pharmaceuticals, Inc. | Mark J Rosenblum Exec VP Finance, CFO | $16k 20,000 shares | first purchase |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.